Synthetic isoxazole as antiplatelet agent

References

• Jennings L. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. J Thromb Haemost 2009;102:248–257
   Google Scholar
• Angiolillo D, Capodanno D, Goto S. Platelet thrombin receptor antagonism and athetothrombosis. Eur Heart J 2010;31:17–28
   PubMed Web of Science ®Google Scholar
• Fuentes QE, Fuentes QF, Andrés V, Pello OM, DeMora JF, Palomo GI. Role of platelets as mediators that link inflammation and thrombosis in aterosclerosis. Platelets 2012;6:1–8
   Google Scholar
• Viallard JF, Solamilla A, Gauthier B, Contin C, De`chanet J, Grosset C, Moreau J-F, Praloran V, Nurden P, Pellegrin J-L, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002;99:2612–2614
   PubMedGoogle Scholar
• Ruggeri ZM. Mechanisms initiating platelet thrombus formation. J Thromb Haemost 1997;78:611–616
   Google Scholar
• Jantan I, Harlina Y, Yasin M, Jalil J, Murad S, Sum M. Antiplatelet aggregation activity of compounds isolated from Guttiferae species in human whole blood. Pharmaceut Biol 2009;47:1090–1095
   Web of Science ®Google Scholar
• Lin CN, Lu CM, Lin HC, Fang SC, Shieh BJ, Hsu MF, Wang JP, Ko FN, Teng CM. Novel antiplatelet constituents from Formosan moraceous plants. J Nat Prod 1996;59:834–838
   Google Scholar
• Chung MI, Weng JR, Wang JP, Teng CM, Lin CN. Antiplatelet and anti-inflamatory constituents and new oxygenated xanthones from Hypericum geminiflorum. Planta Med 2002;68:25–29
   PubMed Web of Science ®Google Scholar
• De Andrade M, Bianco EM, Pereira RC, Texeira VL, Fuly AL. Anticoagulation and antiplatelet effects of a dolastane diterpene isolated from the marine brown alga Canistrocarpus cervicornis. J Thromb Thrombolysis 2011;31:235–240
   Google Scholar
• Tang J, Li HL, Shen YH, Jin HZ, Yan SK, Liu XH, Zeng HW, Liu RH, Tan YX, Zhang WD. Antitumor and antiplatelet activity of alkaloids from Veratrum dahuricum. Phytother Res 2010;24:821–826
   Google Scholar
• Youssef K, Al-Omar M, El-Subbagh H, Abou-Zeid L, Abdel-Gaber AG, Haress N, Al-Tuwaijri S. Synthesis, antiplatelet aggregation activity, and molecular modeling study of novel substituted-piperazine analogues. Med Chem Res 2011;20:898–911
   Web of Science ®Google Scholar
• Sunkel C, De Casa-Juana MF, Cillero FJ, Priego JG, Ortega MP. Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines 1. J Med Chem 1988;31:1886–1890
   Google Scholar
• Altomare C, Summo L, Cellamare S, Varlamov AV, Voskressensky LG, Borisova TN, Carotti A. Pyrrolo[3,2-c]pyridine derivatives as inhibitors of platelet aggregation. Bioorg Med Chem Lett 2000;10:581–584
   Google Scholar
• Xue C-B, Roderick J, Mousa S, Olson R, De Grado W. Synthesis and antiplatelet effects of an isoxazole series of glycoprotein IIb/IIIa antagonist. Bioorg Med Chem Lett 1998;15:3499–3504
   Google Scholar
• Ruthu M, Pradeepkumar Y, Madhusudhana C, Prasanthil G, Java Sankar Reddy V. Pharmacological activities of isoxazole derivatives. J Global Trends Pharmaceut Sci 2011;2:55–62
   Google Scholar
• Batra S, Roy AK, Patra A, Bhaduri P, Surin R, Raghavan SAV, Sharma P, Kapoorb K, Dikshit M. Baylis-Hillman reaction assisted parallel synthesis of 3,5-disubstituted isoxazoles and their in vivo bioevaluation as antithrombotic agents. Bioorg Med Chem 2004;12:2059–2077
   Google Scholar
• Pruitt JR, Pinto DJ, Estrella MJ, Bostrom LL, Knabb RM, Wong PC, Wright MR, Wexler RR. Isoxazolines and isoxazoles as Factor Xa Inhibitors. Bioorg Med Chem Lett 2000;10:685–688
   Google Scholar
• Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963;168:178–195
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 2003;278:30725–30731
   PubMed Web of Science ®Google Scholar
• Antczak A, Singh N, Gay S, Worth RG. IgG-complex stimulated platelets: A source of sCD40L and RANTES in initiation of inflammatory cascade. Cellular Immunol 2010;263:129–133
   PubMed Web of Science ®Google Scholar
• Kiechl S, Muigg A, Santer P, Miterrer M, Egger G, Oberhollenzer M, Oberhollerzer F, Mayr A, Gasperi A, Poewe W, et al. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation 1999;9:614–619
   Google Scholar
• Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;7:2661–2666
   Google Scholar
• Ludwing RJ, Schultz JE, Boehnche W-H, Podda M, Tandi C, Krombach F, Baatz H, Kaufmann R, Adrian UH, Zollner TM. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004;122:830–836
   Google Scholar
• Storey R, Judge HM, Wilcox RG. Stan heptista inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate by Clopidogrel and the P2Y12 receptor antagonist AR-C69931 MX but not Aspirin. Thromb Haemost 2002;88:488–494
   PubMed Web of Science ®Google Scholar
• Harding SA, Sommerfield AJ, Sarma J, Twomey PJ, Newby DE, Frier BM, Fox HAA. Increased CD40 ligand and platelet–monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004;176:2321–2325
   Google Scholar
• Setianto BY, Hartopo AB, Gharini PPR, Anggrahini DW, Irawan B. Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome. Heart Vessels 2010;25:282–287
   PubMed Web of Science ®Google Scholar
• Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix ICA, Winjnands E, Goossens P, Van Kruchten R, Thevissen L, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010;18:4317–4327
   Google Scholar